Objectives: Infections with extended-spectrum-b-lactamase-producing organisms are an increasing public health concern. We reviewed the use of an outpatient parenteral antibiotic therapy (OPAT) programme to facilitate the early discharge from hospital of patients with ESBL-associated urinary tract infections.
Introduction
Extended-spectrum b-lactamases (ESBLs) are enzymes that confer resistance to most b-lactam antibiotics. ESBL-producing bacteria also typically show increased levels of resistance to other agents and therefore treatment options are often limited. Over the past 10 years there has been an increase in the incidence of infections due to ESBL-producing organisms in the UK and globally. 1 ESBL infections are associated with higher mortality and increased costs, and therefore pose a significant new challenge for health services. 2 A parenteral carbapenem is often the only suitable antimicrobial agent. 3 Therefore, patients have to remain in hospital to complete antibiotic therapy, even if they are clinically stable and ambulatory, resulting in increased costs and length of stay.
Outpatient parenteral antibiotic therapy (OPAT) facilitates the discharge from hospital of clinically stable patients with serious infections. The OPAT unit at the Royal Hallamshire Hospital in Sheffield is run by a multidisciplinary team based in the infectious diseases department, and allows patients to attend daily to receive their intravenous antibiotic dose and then go home again immediately afterwards. Infections caused by highly resistant Gram-negative organisms are eminently suitable for this approach, and use of OPAT in this setting is likely to result in improved patient convenience and reduced costs.
Here, we have reviewed all cases of urinary tract infections (UTIs) caused by ESBL-producing isolates that were treated through our OPAT service over a 4 year period.
Methods
Any patient who completed a course of parenteral antibiotics through OPAT for a UTI caused by ESBL-producing bacteria over a 4 year period between 26 January 2006, when the OPAT service was established, and 25 January 2010 was included in the study. Cases were defined as being uncomplicated UTIs if there was no clinical or radiological evidence of upper urinary tract involvement. All data were collected retrospectively from case notes and the OPAT database. We recorded demographic, clinical and laboratory data for all patients. 
Results
Twenty-four OPAT episodes involving 11 patients were identified ( Table 1 ). All patients were referred to OPAT once resistance testing had revealed that there were no oral treatment options available. The mean age was 57.9 years (range 32 -71). Eight of the 11 patients (72.7%) had received three or more courses of antibiotics for UTIs in the 6 months prior to their first OPAT episode; 4 (36.4%) had had previous inpatient treatment for a UTI caused by ESBL-producing bacteria. Six patients (54.5%) had an underlying urological abnormality on presentation to OPAT. Two patients had more than one OPAT episode during the study period. All patients received 1 g of parenteral ertapenem daily, following confirmation of ertapenem susceptibility on resistance testing of the isolate. None of the patients went on to develop an episode of bacteriuria associated with a carbapenem-resistant isolate and, in particular, no ertapenem resistance was detected.
The OPAT episodes are summarized in Table 2 . The mean duration of the OPAT episodes was 9.9 days (range 3-42), while the mean total number of days of parenteral antibiotics, both inpatient and outpatient, used to treat each UTI episode was 11.2 days (range 3 -42). In each case, the duration of treatment was set at the start of the OPAT episode. Three OPAT episodes, involving Patients B, F and H, respectively, were of .2 weeks in duration. In the case of Patients F and H, a decision was made to give a 6 week course of parenteral antibiotics as there was a history of frequently recurring UTIs despite numerous short courses of antibiotics. Patient B was given a 6 week course of antibiotics as he had received a clinical diagnosis of prostatitis. Microbiological clearance of infection, as evidenced by a negative urine culture near the end of an OPAT episode, was not routinely confirmed. However, in 13 of the 24 OPAT episodes, a negative urine culture was obtained within a few days of the completion of the episode. There was only one occasion where, after having undergone OPAT, a patient later required admission for parenteral antibiotics for an ESBL-associated UTI (Patient E). On this occasion, the patient was too unwell to receive treatment through OPAT.
There were no adverse effects related to ertapenem requiring cessation of a course earlier than planned and none of the OPAT episodes ended in a patient requiring readmission. Patient E required an admission for treatment of Clostridium difficile diarrhoea between her second and third OPAT episodes.
Patients requiring multiple OPAT episodes
Patients E and F required 10 and 5 OPAT episodes, respectively, during the study period.
Patient E had a history of recurrent UTIs, but despite extensive urological and immunological investigations, no underlying cause for these was found. The resistance pattern of her ESBLproducing Escherichia coli isolates was identical in all but one of her OPAT episodes (Episode 7). Her OPAT courses lasted between 3 and 14 days. None of her OPAT episodes commenced within 2 weeks of completion of the previous episode.
Patient F had a history of recurrent renal calculi, which were likely acting as a nidus for his recurring UTIs. All five of his OPAT episodes were associated with ESBL-producing isolates of E. coli with identical resistance patterns. In view of the relatively high frequency of recurrence of his ESBL-associated UTIs, he went on to have a 6 week course of parenteral ertapenem, following which he had one further episode of ESBL-associated UTI over 7 months of follow-up.
Discussion
The cases presented here suggest that patients with UTIs caused by ESBL-producing organisms, with no suitable oral antibiotic therapy, can be treated effectively through OPAT programmes with once daily parenteral ertapenem. All the OPAT episodes concluded with clinical resolution of symptoms without the need for readmission. Nine out of 11 patients did not have a recurrent ESBL-associated UTI during the study period, while 2/11 patients had multiple further episodes. In one of these cases, several recurrences occurred shortly after completing a treatment course of short duration, but a longer antibiotic course resulted in more prolonged remission. An increased use of OPAT to treat infections with ESBLproducing organisms would help to limit the growing financial burden on health services caused by the increasing incidence of this type of infection. During the episodes presented here, a cumulative total of 238 days of intravenous antibiotics were administered through OPAT. Had OPAT not been available, these would have been inpatient bed days and, thus, the use of OPAT freed up significant inpatient capacity. Many previous studies have found that OPAT results in a considerable cost saving compared with the equivalent cost of inpatient care. 4 Specifically, OPAT has been shown to be cost-effective within the UK National Health Service framework, incurring 47% of the equivalent national average costs of inpatient care, while at the same time being preferred by patients. 5 Ertapenem is a broad-spectrum carbapenem and an ideal choice for OPAT because of its once daily parenteral dosage. It has been shown to have good in vitro activity against ESBLproducing bacteria. 6 Only limited observational data exist regarding clinical outcomes with ertapenem, but many of these demonstrate high levels of clinical efficacy in the treatment of ESBL-producing infections. 7 We have found ertapenem to be well tolerated in the OPAT setting. Paterson et al. 8 reported that 10.9% of ESBL-positive Klebsiella pneumoniae isolates collected worldwide from intra-abdominal infections were resistant to ertapenem, compared with 4% -5% that were resistant to imipenem and meropenem. Our local microbiology laboratory identified 214 ESBL-producing E. coli isolates in urine samples received between October 2007 and May 2008. Of those, 15 (7%) were resistant to ertapenem, but none was resistant to meropenem (T. Winstanley, unpublished data). These figures suggest that ertapenem remains a viable option in the vast majority of ESBL infections. Reports of the development of carbapenem resistance during carbapenem therapy, including ertapenem, 9 are concerning. This phenomenon requires further assessment as to its frequency and effect on clinical outcomes. Enterobacteriaceae with chromosomal AmpC b-lactamase should be monitored particularly closely for the development of ertapenem resistance due to the risk of outer membrane protein loss in combination with derepression of the AmpC gene. This is a small study, but illustrative of an increasing problem with major implications for healthcare resources and for patients. Only a small proportion of patients with urinary tract infections caused by ESBL-producing organisms were referred to our OPAT service during the study period, but numbers are increasing, particularly since local microbiology reports of ESBL UTIs now specifically mention OPAT as a treatment option if no oral antibiotic is suitable. Since the OPAT service is run by infectious diseases and microbiology specialists, it is likely that the duration of antibiotic therapy was similar to that which would have been given had the patients been treated as inpatients. Community-onset infections caused by ESBL-producing bacteria, in particular CTX-M ESBL-producing E. coli isolates, are also a growing problem. 10 In the future, OPAT schemes may be increasingly used to prevent hospital admissions altogether, by direct referrals from community healthcare services or outpatient clinics, as was the case with some of our patients.
